Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 GP183 | DOI: 10.1530/endoabs.49.GP183

ECE2017 Guided Posters Pituitary (12 abstracts)

Copeptin – a sensitive marker of an altered CRH-axis in pituitary disease

Krzysztof Lewandowski 1 , Andrzej Lewinski 1 , Elzbieta Skowronska-Jozwiak 1 , Katarzyna Malicka 1 , Wojciech Horzelski 2 & Georg Brabant 3


1Department of Endocrinology and Metabolic Diseases, “Polish Mother” Memorial Research Institute and The Medical University of Lodz, Lodz, Poland; 2Faculty of Mathematics and Computer Science, University of Lodz, Lodz, Poland; 3Experimental and Clinical Endocrinology Med Clinic I, University of Luebeck, Lübeck, Germany.


Background: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin (AVP) closely reflects AVP release. Previously it was shown that copeptin is stimulated in standard pituitary function tests acting through hypothalamic centres. Furthermore, copeptin has been shown to subtly mirror stress potentially mediated via CRH. To further test a potential direct interaction of CRH with copeptin release which could augment AVP effects on pituitary function, we investigated copeptin response in a standard CRH test, both in healthy controls and patients with pituitary disease.

Patients and methods: 18 healthy controls and 29 subjects with history of pituitary disease were subjected to a standard CRH test and in addition to ACTH and cortisol we measured copeptin by standard assays (ThermoFisher).

Results: Patients with previous pituitary disease were subdivided in a group passing the test (P1) and failing (P2). The latter group included five patients with diabetes insipidus. The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, P=0.04 for P1+P2) with a maximum increase in controls from 3.84±2.86 pmol/l, to 12.65±24.87 pmol/l, P=0.04, at 30 min). In contrast, both groups of pituitary patients lacked a significant CRH response. The mean increase in P2 was from 1.93±1.44 pmol/l to 3.37±3.49 pmol/l, at 30 min, P=ns, and even in P1 where ACTH concentrations increased four-fold (mean 21.48 vs. 91.53 pg/ml, P<0.01) copeptin did not respond (e.g. 4.35±5.81 pmol/l vs. 5.36±6.79 pmol/l, at 30 min, P=ns).

Conclusions: CRH is able to stimulate copeptin release in healthy controls suggesting a direct interaction of CRH and AVP/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard CRH test indicating i) that the CRH-ACTH-cortisol response is largely independent from the AVP system, but ii) the CRH-AVP interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.